CompletedNot Applicable

International Registry on Cardioversion of Atrial Fibrillation (MK-6621-051)

4,658 participantsStarted 2010-05-25

Plain-language summary

This study will create a prospective registry of consecutive patients with Atrial Fibrillation (Afib) considered for cardioversion treatment to document up-to-date practice of in-hospital treatment, with a focus on the characterization of type of Afib, as well as on treatments applied (drugs, devices, interventions and their combinations), and associated complications within 60 days after enrollment.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participant with documented atrial fibrillation (confirmed by electrocardiogram) in the hospital setting at the time of enrollment * Planned cardioversion (of atrial fibrillation) Exclusion Criteria: * Already enrolled in this or any other clinical trial * Atrial flutter

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission)

Timeframe: Baseline (time of admission)

Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission)

Timeframe: Baseline (time of admission)

Clinical Type of Atrial Fibrillation at Baseline (Admission)

Timeframe: Baseline (time of admission)

Treatments Utilized for Participants for Atrial Fibrillation

Timeframe: At time of Treatment (up to 1 day from admission)

Percentage of Participants Who Had a Successful Electrical or Pharmacological Cardioversion

Timeframe: At time of treatment (up to 1 day from admission)

Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation

Timeframe: up to 60 days from day of treatment (cardioversion)

Trial details

NCT IDNCT01119716

SponsorMerck Sharp & Dohme LLC

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2013-02-15

Results submitted2013-12-13

View on ClinicalTrials.gov More Atrial Fibrillation trials

Plain-language summary

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission)

Timeframe: Baseline (time of admission)

Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission)

Timeframe: Baseline (time of admission)

Clinical Type of Atrial Fibrillation at Baseline (Admission)

Timeframe: Baseline (time of admission)

Treatments Utilized for Participants for Atrial Fibrillation

Timeframe: At time of Treatment (up to 1 day from admission)

Percentage of Participants Who Had a Successful Electrical or Pharmacological Cardioversion

Timeframe: At time of treatment (up to 1 day from admission)

Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation

Timeframe: up to 60 days from day of treatment (cardioversion)